RespireRx Pharmaceuticals Inc (RSPI)

[food4thought]

Neuro could only come up with 2 flat out rejections that may have been similar to CX-717 rejection. I do not have access or the time to retrieve that data, so I am going on his word. You continue to rehash all of this. I agree with you in the sense that pursuing ADHD in the current FDA environment(hindsight) was a substantial risk but what else was Stoll to do with the positive results. He paved an unfamiliar road, learned a valuable lesson at his and our cost, and will concentrate on new and hopefully more fruitful efforts. I am just asking you to focus on the present and offer posts of value rather than wreckless rants. Losing money sucks...you can learn from data presented here and hope to recoup your losses by timing new binary events or pout in the corner and sling poop like a mindless monkey. The choice is yours.